Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054816 | 1.00 | LMNA (0.61) | LMNAMAPTSIRT6RECQLRAB9A | |
| SCHEMBL30168945 | 1.00 | LMNA (0.61) | LMNAMAPTSIRT6RECQLRAB9A | |
| SCHEMBL21032675 | 1.00 | LMNA (0.61) | LMNAMAPTSIRT6RECQLRAB9A | |
| SCHEMBL23360714 | 1.00 | LMNA (0.61) | LMNAMAPTSIRT6RECQLRAB9A | |
| SCHEMBL24519809 | 0.84 | LMNA (0.59) | LMNAMAPTSIRT6RECQLRAB9A | |
| SCHEMBL12813151 | 0.84 | LMNA (0.59) | LMNAMAPTSIRT6RECQLRAB9A | |
| SCHEMBL20293508 | 0.83 | MAPT (0.64) | LMNAMAPTSIRT6RECQLALDH1A1 | |
| SCHEMBL23072835 | 0.83 | MAPT (0.64) | LMNAMAPTSIRT6RECQLALDH1A1 | |
| SCHEMBL16054939 | 0.83 | LMNA (0.61) | LMNAMAPTSIRT6RECQLALDH1A1 | |
| SCHEMBL30565923 | 0.83 | MAPT (0.64) | LMNAMAPTSIRT6RECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | claimed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | claimed |
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| EP-2556058-B1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INST (AU) | 2017-06-14 | — | — | EP | disclosed |
| EP-2556058-B1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INST (AU) | 2017-06-14 | — | — | EP | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-05-02 | — | — | US | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| EP-1351946-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2003-10-15 | — | — | EP | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002020500-A2 | MATERIALS AND METHODS TO POTENTIATE CANCER TREATMENT | ICOS CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | LMNA 2670/4885MAPT 19/4885SIRT6 4196/4885 |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | LMNA 834/4885MAPT 4502/4885SIRT6 3230/4885 |
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | NR1H2, NR1H3, NR1I3 | LMNA 584/4885MAPT 4678/4885SIRT6 1519/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | LMNA 3372/4885MAPT 1127/4885SIRT6 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.